49 patients (64.5 %) had luminal breast cancer, 13 (17.1 %) had HER2-positive/ER-positive tumors, 4 (5.3 %) had HER2-positive/ER-negative tumors, and 10 (13.6 %) had triple-negative breast cancer. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.